Cargando…

SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway

BACKGROUND: Small ubiquitin-like modifier specific peptidase 2 (SENP2) suppresses the progression and chemoresistance of several cancers, while few studies report its role in hepatocellular carcinoma (HCC). This study aimed to evaluate the effect of SENP2 on stemness, sorafenib sensitivity, and down...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xiaohui, Liu, Bohao, Zhang, Chen, Tang, Wenbin, Liang, Shitian, Xiao, Yadan, Deng, Ruoyu, Li, Zhuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688154/ https://www.ncbi.nlm.nih.gov/pubmed/34950583 http://dx.doi.org/10.3389/fonc.2021.773045

Ejemplares similares

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma
por: Zheng, Jia, et al.
Publicado: (2022)

An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells
por: Liu, Huayuan, et al.
Publicado: (2022)

Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway
por: Shao, Hui, et al.
Publicado: (2023)

CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma
por: Li, Bowen, et al.
Publicado: (2021)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma
por: Zhang, Shuaishuai, et al.
Publicado: (2020)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma
por: Hu, Hejuan, et al.
Publicado: (2021)

ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy
por: Kong, Jian, et al.
Publicado: (2020)

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2021)

Transcriptomic Characterization of Hepatocellular Carcinoma with CTNNB1 Mutation
por: Ding, Xiao, et al.
Publicado: (2014)

p53 Affects PGC1α Stability Through AKT/GSK-3β to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer
por: Deng, Xinyue, et al.
Publicado: (2020)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
por: Chen, Siqi, et al.
Publicado: (2023)

Case Report: Targeted Therapy for Metastatic Solid Pseudopapillary Neoplasm of the Pancreas With CTNNB1 and PTEN Mutations
por: Wang, Xinbo, et al.
Publicado: (2021)

Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA
por: Li, Yiming, et al.
Publicado: (2022)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer
por: Zhang, Yi, et al.
Publicado: (2021)

Discovery of a Dual SENP1 and SENP2 Inhibitor
por: Brand, Michael, et al.
Publicado: (2022)

Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment
por: Zhang, Chen, et al.
Publicado: (2023)

PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer
por: Ozcan, Gulnihal
Publicado: (2023)

Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy
por: Dong, Wei, et al.
Publicado: (2021)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Zhang, Xia, et al.
Publicado: (2023)

CDX2/mir-145-5p/SENP1 Pathways Affect LNCaP Cells Invasion and Migration
por: He, Jin-Hua, et al.
Publicado: (2019)

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma
por: Hashiba, Tomomi, et al.
Publicado: (2020)

SENP1 and SENP2 regulate SUMOylation of amyloid precursor protein
por: Maruyama, Takuma, et al.
Publicado: (2018)

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
por: Cai, Wenpeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tu2mctsf2a1csr3q3a0d4kfnqi